UNICYCIVE THERAPEUTICS, INC. (UNCY) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Current obligations | 18.70M USD | Liabilities, Current |
| Cash and equivalents | 44.19M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 17.24M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $18.70M | $44.19M | $17.24M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $26.48M | $37.37M | $17.21M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $18.94M | $29.20M | $12.07M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $13.13M | $42.70M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $13.57M | $22.33M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $16.68M | $19.77M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $24.12M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $10.46M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $13.09M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $30.28M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $17.53M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $15.46M | $14.35M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $15.42M | $18.82M | (m) | (m) | $3.11M | (m) |
| 2023-03-31 | (m) | $15.97M | $24.33M | (m) | (m) | $1.85M | (m) |
| 2022-12-31 | (m) | $3.28M | $455.00K | (m) | (m) | $2.19M | (m) |
| 2022-09-30 | (m) | $5.52M | $7.01M | (m) | (m) | $2.95M | (m) |
| 2022-06-30 | (m) | $2.83M | $10.57M | (m) | (m) | $1.99M | (m) |
| 2022-03-31 | (m) | $2.40M | $13.62M | (m) | (m) | $1.84M | (m) |
| 2021-12-31 | (m) | $2.10M | $16.58M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $785.00K | $18.01M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $5.12M | $1.00K | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $2.88M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |